Zoomlogi is our one-stop shop for everything we ship.
Minaris × Zoomlogi at a glance
In cell and gene therapy, shipment performance can directly affect patient treatment timelines. Multiple specialty couriers unified in one platform. 20+ features co-developed. >95% on-time delivery. ~70% reduction in average delay duration. Part 11-capable chain-of-custody documentation with seven-year retention, providing a foundation for future validation. Real-time shipment visibility extended to Minaris' clients. Now live at two sites.
A Partnership Built Around the Patient
Minaris Advanced Therapies is the CDMO Business Unit of Minaris, dedicated to cell and gene therapies, a field where every shipment has a direct impact on a patient's life. Inbound, apheresis material arrives from collection centers around the world, carrying the biological starting point of a patient's own treatment. Outbound, finished autologous and allogeneic therapies move to clinics on timelines built around a patient's infusion window. For many programs, especially autologous therapies, there may be limited ability to replace material or recover from a missed treatment window. Every shipment is one patient's treatment, and every delay may have a direct impact to a patient's life.
As a dedicated cell and gene therapy CDMO Minaris selected Zoomlogi to deliver a logistics platform purpose-built for the demands of cell and gene therapy and for the patients whose lives depend on it.
“Six couriers, once scattered across portals, emails, and calendars, are now one platform with chain of custody on every shipment. We went live in days, with no IT involvement.”
Edna Choi – VP Supply Chain, Minaris Advanced Therapies
Purpose-Built for CGT
Zoomlogi handles every shipment - inbound patient material and outbound finished therapy - in a single platform. Booking, tracking, chain of custody, and reporting all live in one place, tagged by patient program, modality, and site for full end-to-end traceability across the CGT supply chain.
The platform provides 21 CFR Part 11 capable controls and seven-year retention, providing the foundation for future validation as a GMP system. Every action is time-stamped and attributable, giving Minaris a complete, auditable record of shipment activity that complements its existing validated quality systems.
The platform was shaped by the Minaris team from day one. Since January 2026, Zoomlogi has co-developed 20+ features alongside Minaris leveraging decades of experience in the CGT development and manufacturing space now available in production for every Zoomlogi customer.
Greater Transparency for CGT Clients
At the heart of the Minaris–Zoomlogi partnership is a commitment to transparency for the clients they serve and, ultimately, for the patients waiting on the other end of every shipment. Therapy developers gain real-time visibility into inbound patient starting material and outbound therapy delivery to clinics.
For Minaris' clients, this means stronger program oversight, more confident patient scheduling, and a closer partnership with their CDMO. For patients, it means every hand-off, from apheresis to infusion, is visible, tracked, and accountable.
The System Acts, Not Just Watches
A late shipment in cell and gene therapy is not a logistics problem. It is a patient whose infusion window is at risk. When a delivery runs past its window, Zoomlogi's AI voice agent contacts the carrier directly during business hours and logs the full transcript to the shipment record. Since deployment, average delay duration on affected shipments has dropped 70% - time recovered directly on behalf of the patients Minaris and its clients serve.
This capability helps logistics teams respond earlier, document actions consistently, and recover time when delays occur.
What’s Next
With its Philadelphia facility established as the model, Minaris has extended the platform to its Allendale, New Jersey site, going-live in July 2026.
Minaris and Zoomlogi will continue to advance the platform to support greater shipment visibility, stronger documentation, and more responsive logistics workflows for cell and gene therapy programs. The partnership reflects Minaris’ commitment to practical, patient-focused manufacturing support across the development and commercialization pathway.
